Technical Analysis for ALLR - Allarity Therapeutics, Inc.

Grade Last Price % Change Price Change
C 8.23 0.98% 0.08
ALLR closed up 0.98 percent on Thursday, January 20, 2022, on 73 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical ALLR trend table...

Date Alert Name Type % Chg
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Closing Low Bearish 0.98%
Hot IPO Pullback Bullish Swing Setup 0.98%
Narrow Range Bar Range Contraction 0.98%
NR7 Range Contraction 0.98%
Inside Day Range Contraction 0.98%
Down 3 Days in a Row Weakness 0.98%
Down 4 Days in a Row Weakness 0.98%
Down 5 Days in a Row Weakness 0.98%
Older End-of-Day Signals for ALLR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 14 hours ago
Up 2% about 14 hours ago
60 Minute Opening Range Breakout about 15 hours ago
Up 1% about 15 hours ago
Down 5% about 16 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Allarity Therapeutics, Inc. Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Drugs Health Sciences Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome

Is ALLR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.2
52 Week Low 7.13
Average Volume 46,876
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 9.58
Average True Range 1.72
ADX 0.0
+DI 10.37
-DI 21.45
Chandelier Exit (Long, 3 ATRs) 13.04
Chandelier Exit (Short, 3 ATRs) 12.29
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line -0.59
MACD Signal Line -0.27
MACD Histogram -0.3294
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.31
Resistance 3 (R3) 9.25 8.82 9.13
Resistance 2 (R2) 8.82 8.55 8.86 9.07
Resistance 1 (R1) 8.53 8.38 8.68 8.59 9.01
Pivot Point 8.10 8.10 8.18 8.14 8.10
Support 1 (S1) 7.81 7.83 7.96 7.87 7.45
Support 2 (S2) 7.38 7.66 7.42 7.39
Support 3 (S3) 7.09 7.38 7.33
Support 4 (S4) 7.15